Dicerna CEO fears insider trading crackdown, withdraws own shares from Novo Nordisk offer

Novo Nordisk's cash tender offer to acquire all outstanding Dicerna shares no longer includes CEO Douglas Fambrough's personal shares, according to documents amending the original filing to the US Securities and Exchange Commission (SEC).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app